The presence of the progesterone receptor marks this tumor as hormone-responsive and indicates that hormone therapy should be considered as a component of her adjuvant therapy. In some breast cancer ...
A preoperative trial shows that activating the progesterone receptor with low-dose megestrol can deepen estrogen blockade and curb tumor proliferation, without added toxicity, pointing to a simpler ...
Most ER-positive breast cancers are also PR-positive. 1 A small percentage of breast cancers are ER-negative but PR-positive. Breast cancers that lack estrogen receptors are called estrogen ...
Herein, we present a case of HR-negative, HER2-positive metastatic breast cancer (mBC) refractory to numerous lines of therapy. Ultimately, biopsy of a metastatic lesion demonstrated a PI3KCA mutation ...
– evERA met its co-primary endpoints; giredestrant plus everolimus demonstrated significant benefit in ITT and ESR1-mutated populations in the post-CDK inhibitor setting, compared with standard of ...
A number of tumor and host characteristics have been found useful in predicting the risk of recurrence and the chance of death from breast cancer following primary surgery. Traditional prognostic ...
– Filing acceptance based on Phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results